In 2004, the American Psychiatric Association published a paper supporting the use of the antidepressant citalopram (Celexa) in children and teens. After reanalyzing the data, however, researchers found no difference between the drug and placebo. It also became evident that the original study misrepresented the data and was ghostwritten, in large part, by industry insiders. Journal editors continue to refuse to retract the original study in the face of rampant criticism, and, as a result, the paper continues to be cited uncritically.
More:
Interview: Researchers Deconstruct Ghostwritten SSRI Trial
www.madinamerica.com/…/researchers-deconstruct-ghostwritten-industry- trial-for-antidepressant/
| May 14, 2016 … Researchers take a closer look at a trial of citalopram (Celexa) that was ghostwritten and then used to get FDA approval with children. |
What sort of lofty terminology and inspiring language will we read to “prove” that medical treatment is actually for treating the shrinkage in the providers’ and suppliers’ bank accounts and not for treating patients.
Report comment
Should have ended sentence with a question mark. My bad.
Report comment